Rimtuzalcap
规格
| Cas Number | 2167246-24-2 |
| 规格或纯度 | ≥99% |
| 纯度 | ≥99% |
| 包装 | 100mg 或 50mg 或 10mg 或 5mg 或 25mg |
产品信息
| 品牌 | 阿拉丁 |
| 溶解性 | DMSO : 250 mg/mL (660.64 mM; Need ultrasonic) |
| 过滤标签 | Potassium Channel,膜转运器/离子通道 |
| 储存温度 | 避光,-80℃储存 |
| 运输条件 | 超低温冰袋运输 |
| 生化和生理学机理 | Rimtuzalcap (CAD-1883) 是小传导钙激活钾通道（SK 通道）的第一类选择性正异位调节剂。Rimtuzalcap 可用于运动障碍的研究，包括本质性震颤 (ET) 和肢体运动障碍。 |
| 英文描述 |
Rimtuzalcap (CAD-1883) is a first-in-class selective positive allosteric modulator of small-conductance calcium-activated potassium channels (SK channels). Rimtuzalcap can be used for the research of movement disorders including essential tremor (ET) and spinocerebellar ataxia (SCA). In Vitro Rimtuzalcap (Compound 1) is a small molecule modulator of potassium ion channels showing great therapeutic potential for treating a variety of diseases characterized by dysfunction of potassium ion channels and dysfunction from other causes which influence these potassium channels. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo Rimtuzalcap (CAD-1883) reduces the firing rate of Purkinje cells by approximately 40%, consistent with the anticipated therapeutic mechanism of positive allosteric modulation of SK channels. Sequential bath application of 1 or 3 µM CAD-1883 results in a partial reversal of the increased coefficient of variation of the interspike interval which is seen in cerebellar slices from 11-month-old spinocerebellar ataxia-2 58Q mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid |